26 research outputs found
Could a neurological disease be a part of Mozartās pathography? [NeuroloÅ”ki aspekt Mozartove patografije]
As expected, since we recently celebrated the 250th anniversary of birth of Wolfgang Amadeus Mozart, there has been again a renewal of interest in his short but intensive life, as well as in the true reason of his untimely dead. Mozart lived and died in time when the medical knowledge was based mostly on subjective observations, without the established basics of standardized medical terminology and methodology. This leaves a great space for hypothesizing about his health problems, as well as about the cause of his death. The medical academic community attributed to Mozart approximately 150 different medical diagnoses. There is much speculation on the possible causes of Mozartās death: uremia, infection, rheumatic fever, trichinellosis, etc. Recently some authors have raised the question about a possible concomitant neurological disease. According to available records, Mozart has shown some elements of cyclotimic disorder, epilepsy and Gilles de la Tourette syndrome. Furthermore, the finding of a temporal fracture on (allegedly) Mozartās skull, gives a way to speculations about the possibility of a chronic subdural hematoma and its compressive effect on the temporal lobe. Despite numerous theories on Mozartās pathography that also include a concomitant neurological disorder, the medical and history records about Mozartās health status indicate that he probably had suffered from an infective illness, followed most likely by the reactivation of rheumatic fever, which was followed by strong immunologic reaction in the last days of his life. Taking all the above into consideration, it is reasonably to conclude that Mozartās neurological disturbances were caused by the intensity of the infective disease, and not primarily by a neurological disease
Farmakogenetika citotoksiÄnog lijeÄenja kolorektalnog karicinoma
Colorectal cancer is a relatively common tumor with incidence that has been increasing during recent decades. Despite the rapid advances in treatment of colorectal cancer, the best way to combine and sequence all available drugs to optimize treatment is not yet established. The majority of cytotoxic drugs used in therapy of colorectal cancer have a dose related effect and narrow therapeutic index. Hence, dosing of cytotoxic drugs is considered very important. Current modalities for therapy and dose selection give restricted possibilities to equalise inter-individual variations which are dependent on physiological, genetic and environmental factors. In this article, an overview of current possibilities of personalized medicine in therapy of colorectal cancer is presented. This includes review of the most important gene polymorphisms important for safety and efficacy of cytotoxic therapy in colorectal cancer, and evaluation of their importance for the current clinical practice. Despite raising knowledge, providing individual treatment with low toxicity and significant benefits is still an unsolved problem. Reasons for this are the lack of knowledge on distribution of these polymorphisms in the population, importance of non-genetic factors, price of genetic testing and still limited data from controlled clinical trials confirming the clinical usefulness of pharmacogenetic testing. Although the initial costs of cancer management and personalized medicine may be high, in the future they may result in significant benefits from both a clinical and economical perspective.Rak kolorektuma relativno je Äest tumor s rastuÄom incidencijom zadnjih desetljeÄa. UnatoÄ brzom napretku u lijeÄenju kolorektalnog raka, joÅ” nije jasno na koji naÄin je najbolje kombinirati i kojim redoslijedom koristiti dostupne lijekove. VeÄina citotoksiÄnih lijekova koji se primjenjuju u lijeÄenju kolorektalnog raka imaju uÄinak ovisan o dozi i malu terapijsku Å”irinu te je odreÄivanje doze lijeka vrlo znaÄajno. VažeÄi naÄini izbora terapije i odreÄivanja doze daju ograniÄene moguÄnosti ublažavanja interindividualnih varijacija ovisnih o fizioloÅ”kim, genetiÄkim i okoliÅ”nim Äimbenicima. U ovom Älanku dan je pregled trenutaÄnih moguÄnosti individualiziranja lijeÄenja kolorektalnog raka. To ukljuÄuje pregled najznaÄajnihih genetskih polimorfizama bitnih za sigurnost i uÄinkovitost citotoksiÄne terapije u lijeÄenju kolorektalnog raka te evaluaciju njihove znaÄajnosti za trenutaÄnu kliniÄku praksu. UnatoÄ sve veÄem znanju, omoguÄavanje individualiziranog lijeÄenja uz ograniÄavanje toksiÄnosti a potenciranje uÄinkovitosti joÅ” je nerijeÅ”eni problem. Razlog za to su manjak znanja o distribuciji polimorfizama u populaciji, važnosti negenetiÄkih Äimbenika, cijena genetiÄkog testiranja i joÅ” uvijek ograniÄeni podaci iz kontroliranih kliniÄkih studija koji bi potvrdili kliniÄku korisnost farmakogenetiÄkog testiranja. Iako inicijalni troÅ”kovi lijeÄenja kolorektalnog raka i personalizirane medicine mogu biti visoki, u buduÄnosti bi kombinacija ovih pristupa mogla rezultirati znaÄajnim prednostima iz kliniÄke i ekonomske perspektive
MASSIVE CLOZAPINE OVERDOSE: WHAT TO EXPECT?
Clozapine is an atypical antipsychotic drug indicated
for treatment-resistant schizophrenia. Despite its superior
clinical efficacy, many deleterious adverse events, including agranulocytosis, have resulted in its more
judicious use (Asenjo Lobos et al. 2010).
The most frequently reported symptoms of clozapine
intoxication are impaired alertness and tachycardia;
other symptoms include: hyperthermia, alterations in
consciousness, dysarthria, ataxia, seizures, cardiac arrhythmias, excessive bronchial mucus, hypersalivation,
miosis, blood dyscrasias, pancreatitis and hepatitis (Le
Blaye et al. 1992, KrƤmer et al. 2010). Studies that
evaluated the case fatality rate with various antipsychotics concluded that clozapine was far more toxic than
other antipsychotics (Ferrey 2018).
To the best of our knowledge, this is the fist case
report describing treatment and outcomes following a
massive overdose of clozapine, amounting to 46.7 times
the recommended patientās daily dose of clozapine
Drugs and Pregnancy
Znanje o sigurnosti lijekova primijenjenih tijekom trudnoÄe vrlo je važno za sve lijeÄnike kliniÄare. S obzirom na to da je 50-ak posto trudnoÄa neplanirano, uÄestalo se javlja pitanje uÄinka ekspozicije lijekovima u ranom i najosjetljivijem razdoblju joÅ” neotkrivene trudnoÄe. S druge strane, mnogo žena s bolestima koje treba lijeÄiti kroniÄnom terapijom planira trudnoÄu. Iako je malen broj lijekova Äija je primjena u trudnoÄi kontraindicirana zbog dokazanih Å”tetnih utjecaja na majku i dijete, opÄenito postoji velik strah od primjene lijekova u trudnoÄi, Å”to kao problem donosi nedovoljno ili neadekvatno ili pak pretjerano propisivanje lijekova. Neprimjerene preporuke mogu dovesti do nepotrebnog prekida ili neprimjerenog lijeÄenja kroniÄnih ili akutnih bolesti tijekom trudnoÄe, Å”to može povisiti rizik od njezina nepovoljnog ishoda. Kod odluke o primjeni lijekova u trudnice treba provesti ovaj pristup: 1. procijeniti potrebu za primjenom lijeka; 2. izabrati najsigurniji lijek; 3. pratiti primjenu lijeka; 4. dati specifiÄne upute o primjeni (npr., izbjegavati odreÄene kombinacije lijekova); 5. tražiti savjet kliniÄkog farmakologa ako je potrebno. U Älanku se daje pregled racionalne terapije najÄeÅ”Äih bolesti i stanja tijekom trudnoÄe i dojenja.Knowledge about safety and efficacy of drugs prescribed during pregnancy and lactation is important for every clinician. Due to the fact that approximately 50% of pregnancies are unplanned, there is concern about possible adverse drug reactions (ADR) of drugs taken during the early and most vulnerable stage of pregnancy. Furthermore, many women with chronic illnesses that require treatment are planning to become pregnant. Although there is limited number of drugs that are contraindicated during pregnancy due to their teratogenic or other ADR, there is much fear about prescribing drugs to pregnant women. This raises as much concern about under prescribing drugs as overprescribing them. Inadequate recommendations on drug use during pregnancy may lead to unnecessary therapy cessation or inadequate therapy of chronic or acute illnesses leading to increased risk for adverse pregnancy outcomes. When consulting on pharmacotherapy during pregnancy, physicians should take the following approach: 1. Determine if drug therapy is necessary; 2. Choose the safest drug available; 3. Monitoring drug therapy (e.g. measurement of plasma drug concentration, ADR); 4. Advice on drug use (e.g. avoiding specific drug-drug combinations); 5. Seek advice from clinical pharmacologist. This article provides a review of rational pharmacotherapy for the most common clinical conditions during pregnancy
Use of gastroprotective agents in recommended doses in hospitalized patients receiving NSAIDs: a drug utilization study
OBJECTIVE: In recent years, studies investigated to what extend recommendations for co-prescribing gastroprotective agents in prevention of NSAID-induced gastrointestinal complications are followed in clinical practice. However, only a few studies have also taken into consideration the recommended dose of gastroprotectives prescribed in NSAID-induced ulcer prophylaxis. The aim of our study was to evaluate the prevalence of concomitant use of gastroprotectives with NSAIDs in hospitalized patients, with emphasis on the recommended dose of gastroprotectives for ulcer prophylaxis. - - - - - METHOD: This observational, cross-sectional, drug utilization study included all adult patients receiving NSAIDs hospitalized in the Clinical Hospital Center Zagreb on the day of the study. Data on age, sex, comorbidities, indications for NSAID use, type/dose of NSAIDs and gastroprotectives, history of gastrointestinal events, active gastrointestinal symptoms and risk factors were evaluated. - - - - - MAIN OUTCOME MEASURE: Study outcomes were: (1) prevalence of prescription of gastroprotectives among NSAID-users at risk; (2) prevalence of prescription of gastroprotective in recommended dose; (3) association between risk factors and prescription of GPAs. - - - - - RESULTS: The rates of gastroprotectives prescription were significantly higher in NSAID-users with concomitant risk factors as compared to patients without risk factors [47/70 (67.1%) and 8/22 (36.4%), respectively; p = 0.01072]. However, gastroprotection in recommended ulcer-preventive dose was low in both groups [8/70 (11.4%) and 9/92 (9.8%), respectively]. The number of concomitant risk factors did not increase the odds of receiving anti-ulcer therapy (odds ratio 0.7279). Thirty-three percent of patients with concomitant risk factors were not prescribed gastroprotectives. Ibuprofen, NSAID with the lowest risk of inducing gastrointestinal complications, was prescribed in only two patients. - - - - - CONCLUSION: The results indicate high awareness among hospital physicians about possible NSAID-induced gastrointestinal complications, but insufficient knowledge about risk factors related to NSAID-induced gastrointestinal toxicity, recommended dose of gastroprotectives in NSAID-induced ulcer prophylaxis and gastrointestinal toxicity of different types of NSAIDs
Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital
The relationship between antibiotic consumption and selection of resistant strains has been studied mainly by employing conventional statistical methods. A time delay in effect must be anticipated and this has rarely been taken into account in previous studies. Therefore, distributed lags time series analysis and simple linear correlation were compared in their ability to evaluate this relationship. Data on monthly antibiotic consumption for ciprofloxacin, piperacillin/tazobactam, carbapenems and cefepime as well as Pseudomonas aeruginosa susceptibility were retrospectively collected for the period April 2006 to July 2007. Using distributed lags analysis, a significant temporal relationship was identified between ciprofloxacin, meropenem and cefepime consumption and the resistance rates of P. aeruginosa isolates to these antibiotics. This effect was lagged for ciprofloxacin and cefepime [1 month (R=0.827, P=0.039) and 2 months (R=0.962, P=0.001), respectively] and was simultaneous for meropenem (lag 0, R=0.876, P=0.002). Furthermore, a significant concomitant effect of meropenem consumption on the appearance of multidrug-resistant P. aeruginosa strains (resistant to three or more representatives of classes of antibiotics) was identified (lag 0, R=0.992, P<0.001). This effect was not delayed and it was therefore identified both by distributed lags analysis and the Pearson's correlation coefficient. Correlation coefficient analysis was not able to identify relationships between antibiotic consumption and bacterial resistance when the effect was delayed. These results indicate that the use of diverse statistical methods can yield significantly different results, thus leading to the introduction of possibly inappropriate infection control measures
Pain Relief in Medical Patients: Does Clinical Judgment and Prescribing Knowledge Suffice?
The aim of this study was to evaluate the quality of pain management in hospitalised patients. A cross-sectional study
design that included all medical patients experiencing pain was used. Out of 167 patients hospitalized at the Department
of Medicine at the University Hospital Zagreb, 41 patients were experiencing pain and 40 out of them received analgesics.
Twenty-two out of 38 patients were treated for malignant pain, 16 for non-malignant pain, and 2 patients could not be
classified. Adequate pain relief was reported in less than 25% of patients in both groups. Our study revealed under-prescribing
of combination therapy, low utilization rates of strong opioids and prevailing Ā»as neededĀ« prescribing practice.
In conclusion, unsatisfactory pain management in medical patients is often present if left solely to the clinical judgement
and knowledge of the prescribing physician. Regular pain assessment, evidence-based guidelines, education and regular
audits of implementation of these measures are a prerequisite for effective pain treatment, and should all be employed in
patients experiencing pain
Antibiotic Use Optimization Program in the Largest Croatian University Hospital ā Benefits of Restrictions on Unlimited Antibiotic Use
The aim of this study was to obtain the relevant information on antibiotic use in a 750-bed Croatian university hospital.
The study has been designed as a 2-point prevalence interventional analysis. For each patient on antibiotic therapy,
diagnosis, indication for treatment, antibiotic therapy, dosage and route of administration together with the results of
microbiological studies (if available) were obtained. After the first prevalence analysis in 2001, a restriction on unlimited
antibiotic use was introduced. The second analysis, performed in 2002, after restrictions on antibiotic use, revealed reductions
in the rates of restricted release antibiotics and overall antibiotic use with decreases from 38.6% to 36.9% and
23.4% to 23.2% respectively (p=0.87). The first survey showed that the 5 most often prescribed antibiotics in the therapy
of bacterial infections were: gentamicin, other aminoglycosides, carbapenems, amoxycillin+clavulanate and vancomycin
with proportions of 14.8%, 10.3%, 8.2%, 7% and 7% respectively. In the year 2002, the most prescribed antimicrobial
drugs in the therapy of bacterial infections were: gentamicin, quinolones, vancomycin, carbapenems and cefuroxime with
proportions of 18.6%, 11.4%, 9.7%, 9.3% and 8% respectively. A reduction in the proportions of doubtful antibiotic therapy,
from 24.6% before the intervention, to 24.2% after the restrictions, accompanied by a 0.4% rise in the rates of indicated
antibiotic therapy was also observed (p=0.93). Our study shows that restrictions on formerly unlimited use of
antimicrobials, even when leading to an improvement in their prescribing, do not necessarily cause rapid and significant
reduction in the overall use of antibiotics or explicit positive financial effects
Two-year Rehospitalization Rates of Patients with Newly Diagnosed or Chronic Schizophrenia on Atypical or Typical Antipsychotic Drugs: Retrospective Cohort Study
Cilj Odrediti smanjuju li atipiÄni antipsihotiÄki lijekovi stopu rehospitalizacije bolesnika s novodijagnosticiranom ili kroniÄnom shizofrenijom viÅ”e nego tipiÄni lijekovi.
Postupci Od 1. sijeÄnja 2003. do 31. prosinca 2004. retrospektivno smo usporeÄivali dvogodiÅ”nje stope rehospitalizacije 135 bolesnika s novodijagnosticiranom i 398 bolesnika s kroniÄnom shizofrenijom (62%, odnosno 65% muÅ”karaca) koji su otpuÅ”teni s lijeÄenja u Psihijatrijskoj bolnici VrapÄe u Zagrebu u razdoblju izmeÄu 1. sijeÄnja 2002. do 31. prosinca 2002. a bili su im prepisani atipiÄni (olanzapin, risperidon ili klozapin) ili tipiÄni (haloperidol ili flufenazin) antipsihotici. Vrijeme do ponovnog primanja u bolnicu odreÄeno je Kaplan-Meierovom formulom za analizu preživljenja.
Rezultati Za vrijeme dvije godine koliko je trajalo praÄenje rehospitalizirana su 52 (39%) bolesnika s novodijagnosticiranom i 197 (47%) bolesnika s kroniÄnom shizofrenijom. Nije bilo znaÄajnih razlika u vremenu do rehospitalizacije s obzirom na vrstu uzimanog lijeka izmeÄu bolesnika s novodijagnosticiranom (P=0,378) i bolesnika s kroniÄnom shizofrenijom (P=0,531).
ZakljuÄak. Stopa rehospitalizacije u bolesnika kojima su prepisani atipiÄni antipsihotici bila je sliÄna stopi u bolesnika kojima su prepisani tipiÄni antipsihotici i za bolesnike s novodijagnosticiranom i za bolesnike s kroniÄnom shizofrenijom.Aim To determine if atypical antipsychotic agents reduce the rehospitalization
rates of patients with newly diagnosed or chronic schizophrenia
in comparison with typical antipsychotic drugs.
Methods From January 1, 2003, to December 31, 2004, we retrospectively
compared two-year rehospitalization rates of 135 patients with newly
diagnosed schizophrenia and 398 patients with chronic schizophrenia
(62% and 65% men, respectively), who were initially discharged from
VrapÄe Psychiatric Hospital, Zagreb, with the prescription of atypical
(olanzapine, risperidone or clozapine) or typical (haloperidol or fluphenazine)
antipsychotic treatment between January 1, 2002 and December
31, 2002. Time-to-readmission was determined with Kaplan-Meier formula
for survival analysis.
Results In the two-year follow-up, 52 (39%) newly diagnosed patients
and 197 (47%) patients with chronic schizophrenia were rehospitalized.
No significant differences in time-to-rehospitalization were observed
with respect to the type of medications in patients with newly diagnosed
schizophrenia (P = 0.378) or patients with chronic schizophrenia
(P = 0.531).
Conclusions. Rehospitalization rates of patients who were prescribed
atypical antipsychotic drugs were similar to those of patients who were
prescribed typical antipsychotic drugs for both the group with the first
psychotic episode and group with chronic schizophrenia